Prognostic Value of Combined Detection of Tumor-Infiltrating CD3+and CD4+T Cells and IL-17 in Non-Small Cell Lung Cancer
[Objective]To investigate the prognostic value of combined detection of tumor-infiltrating CD3+and CD4+T cells and interleukin-17(IL-17)in non-small cell lung cancer(NSCLC).[Methods]A total of 132 NSCLC pa-tients who underwent radical lung cancer surgery in our hospital were followed up for 3 years postoperatively.Factors af-fecting patient prognosis and survival status were analyzed,and the expression levels of CD3+and CD4+T cells and IL-17 were compared between disease-free and recurrent patients,along with their relationship to prognosis.[Results]The counts of CD3+and CD4+T cells in the disease-free group were higher than those in the recurrence group(P＜0.05),and the positive expression rate of IL-17 in the disease-free group was lower than that in the recurrence group(P＜0.05).Multi-variate logistic regression analysis showed that tumor staging,CD34 and CD4+cell counts,and IL-17 positivity were fac-tors affecting disease-free survival in NSCLC patients(P＜0.05).Receiver operating characteristic(ROC)curve analysis indicated that the sensitivity of CD3+T cells,CD4+T cells,IL-17,and their combination in predicting disease-free surviv-al in NSCLC patients were 72.22％,75.93％,70.37％,and 81.48％,respectively,and the specificities were 73.44％,71.88％,70.31％,and 90.63％,respectively.The disease-free survival curves for patients with high expression of CD3+and CD4+T cells were better than those for patients with low expression(P＜0.05),and the disease-free survival curve for the IL-17 negative expression group was better than that for the IL-17 positive expression group(P＜0.05).[Conclu-sion]The CD3+T cells,CD4+T cells,and IL-17 are associated with the prognosis of NSCLC,and the combined predic-tion of these three markers has good prognostic value.Patients with low expression of CD3+and CD4+T cells and positive expression of IL-17 have a higher risk of poor prognosis.
万方数据
